Gastrointestinal Stromal Tumor
📧 Sign up to get email alerts when something new happens for Gastrointestinal Stromal Tumor.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-02-11EMA Authorised: Qinlock (ripretinib) — Deciphera Pharmaceuticals (Netherlands) B.V.
The EMA has authorised Qinlock (ripretinib) for use in adults with gastrointestinal stromal tumors, and the medicine carries orphan designat…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
A real-world clinical trial update reports on the safety and efficacy of avapritinib in Chinese patients with gastrointestinal stromal tumor…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) [Phase 1, Phase 2]
A master protocol to evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) across Phase 1 and Phase 2 is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) [Phase 1]
Kura Oncology is conducting a Phase 1 study of Ziftomenib in combination with Imatinib for advanced gastrointestinal stromal tumors, and the…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors [Phase 3]
A Phase 3 randomized trial compares CGT9486 plus sunitinib versus sunitinib alone in advanced or metastatic gastrointestinal stromal tumors;…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-20Clinical Trial Update: Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib [Phase 4]
Phase 4 trial results update on using nilotinib as first-line therapy for metastatic or unresectable gastrointestinal stromal tumors (GIST);…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. [Phase 2]
A Phase 2 clinical trial is evaluating regorafenib in selected GIST mutation subtypes after imatinib, in the second-line setting. The study …
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
Clinical trial update on an oncogenetic panel and integrated clinical data registry study in wild-type gastrointestinal stromal tumor patien…
-
EMA approval · 2026-01-09EMA Authorised: Ayvakyt (avapritinib) — Blueprint Medicines (Netherlands) B.V.
The European Medicines Agency authorised Ayvakyt (avapritinib) for gastrointestinal stromal tumors with conditional approval and orphan desi…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Ongoing Stanford University clinical trial evaluating clinical and pathological aspects of upper gastrointestinal cancers, including stomach…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib [Phase 3]
Phase 3 trial comparing ripretinib to sunitinib in adults with advanced gastrointestinal stromal tumor (GIST) harboring KIT exon mutations a…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors [Phase 1]
Phase I clinical trial update evaluating dose, pharmacokinetics, and safety of Lutetium-177-edotreotide therapy in pediatric participants wi…
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)
A completed clinical trial assessing patterns of care and outcomes in patients with metastatic gastrointestinal stromal tumors (METAGIST).
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: A Comprehensive, Multinational GIST Registry
A comprehensive multinational registry study for gastrointestinal stromal tumor (GIST) that is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: Ripretinib (QINLOCK®) According to Current SmPC
Ripretinib for Gastrointestinal stromal tumor has a completed trial (NCT06619275). The update indicates that the trial findings are consiste…
-
EMA approval · 2025-12-04EMA Authorised: Sunitinib Accord (sunitinib) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Sunitinib Accord for the treatment of gastrointestinal stromal tumors, renal cell carcinoma, and ne…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) [Phase 1, Phase 2]
A clinical trial update describing a Phase 1/2 study of MEK162 in combination with imatinib mesylate for untreated advanced gastrointestinal…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors [Phase 1]
First-in-human Phase 1 trial of IDRX-42 for metastatic and/or unresectable gastrointestinal stromal tumors (GIST) is currently recruiting.
-
EMA approval · 2025-11-12EMA Authorised: Glivec (imatinib) — Novartis Europharm Limited
The European Medicines Agency authorised Glivec (imatinib) for multiple indications, including precursor cell lymphoblastic leukemia-lymphom…
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST [Phase 2]
Update on the SARC044 Phase II trial evaluating the combination of bezuclastinib and sunitinib in patients with gastrointestinal stromal tum…
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies [Phase 1]
Phase Ib study of TNO155 in combination with Spartalizumab or Ribociclib in selected malignancies was terminated, involving multiple indicat…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit [Phase 1]
Phase 1 study evaluating NN3201, a c-Kit targeted antibody-drug conjugate, in advanced and/or metastatic solid tumors expressing c-Kit; curr…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)
A clinical trial update describing a study to profile resistance in refractory gastrointestinal stromal tumor (GIST) using functional imagin…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events [NA]
A clinical trial at MD Anderson Cancer Center is evaluating enhanced outpatient symptom management to reduce acute care visits caused by che…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk [Phase 2]
Phase 2 trial assessing five years of adjuvant imatinib in patients with high-risk gastrointestinal stromal tumors; recruitment is ongoing.